Wu YL - Search Results

1

EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.

Liang Z, Cheng Y, Chen Y, Hu Y, Liu WP, Lu Y, Wang J, Wang Y, Wu G, Ying JM, Zhang HL, Zhang XC, Wu YL. Liang Z, et al. Among authors: wu g, wu yl. Cancer Lett. 2017 Sep 10;403:186-194. doi: 10.1016/j.canlet.2017.06.008. Epub 2017 Jun 19. Cancer Lett. 2017. PMID: 28642172 Review.

2

Co-overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinoma.

Tai AL, Sham JS, Xie D, Fang Y, Wu YL, Hu L, Deng W, Tsao GS, Qiao GB, Cheung AL, Guan XY. Tai AL, et al. Among authors: wu yl. Cancer. 2006 Jan 1;106(1):146-55. doi: 10.1002/cncr.21581. Cancer. 2006. PMID: 16329133 Free article.

3

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.

Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T. Wu YL, et al. J Thorac Oncol. 2007 May;2(5):430-9. doi: 10.1097/01.JTO.0000268677.87496.4c. J Thorac Oncol. 2007. PMID: 17473659 Free article.

4

KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer.

An SJ, Nie Q, Chen ZH, Lin QX, Wang Z, Xie Z, Chen SL, Huang Y, Zhang AY, Yan JF, Wu HS, Lin JY, Li R, Zhang XC, Guo AL, Mok TS, Wu YL. An SJ, et al. Among authors: wu yl, wu hs. J Cancer Res Clin Oncol. 2007 Sep;133(9):635-42. doi: 10.1007/s00432-007-0214-0. Epub 2007 May 4. J Cancer Res Clin Oncol. 2007. PMID: 17479290

5

The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib.

Nie Q, Wang Z, Zhang GC, An SJ, Lin JY, Guo AL, Li R, Gan B, Huang Y, Mok TS, Wu YL. Nie Q, et al. Among authors: wu yl. Eur J Pharmacol. 2007 Sep 10;570(1-3):175-81. doi: 10.1016/j.ejphar.2007.05.015. Epub 2007 Jun 5. Eur J Pharmacol. 2007. PMID: 17597605 Clinical Trial.

6

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals.

Zhu JQ, Zhong WZ, Zhang GC, Li R, Zhang XC, Guo AL, Zhang YF, An SJ, Mok TS, Wu YL. Zhu JQ, et al. Among authors: wu yl. Cancer Lett. 2008 Jul 8;265(2):307-17. doi: 10.1016/j.canlet.2008.02.064. Epub 2008 Apr 14. Cancer Lett. 2008. PMID: 18407408

7

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, Wu YL. Chen HJ, et al. Among authors: wu yl. Pathol Oncol Res. 2009 Dec;15(4):651-8. doi: 10.1007/s12253-009-9167-8. Epub 2009 Apr 21. Pathol Oncol Res. 2009. PMID: 19381876 Free article.

8

The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer.

An SJ, Chen ZH, Lin QX, Su J, Chen HJ, Lin JY, Wu YL. An SJ, et al. Among authors: wu yl. BMC Cancer. 2009 May 12;9:144. doi: 10.1186/1471-2407-9-144. BMC Cancer. 2009. PMID: 19435508 Free PMC article.

9

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Turke AB, et al. Among authors: wu yl. Cancer Cell. 2010 Jan 19;17(1):77-88. doi: 10.1016/j.ccr.2009.11.022. Cancer Cell. 2010. PMID: 20129249 Free PMC article.

10

RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.

Dong S, Guo AL, Chen ZH, Wang Z, Zhang XC, Huang Y, Xie Z, Yan HH, Cheng H, Wu YL. Dong S, et al. Among authors: wu yl. J Hematol Oncol. 2010 Mar 13;3:10. doi: 10.1186/1756-8722-3-10. J Hematol Oncol. 2010. PMID: 20226083 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,366 results

Search Page

Filters